金奧博(002917.SZ):中標1264萬元現場混裝重銨油炸藥車、現場混裝乳化炸藥車採購招標(一標段、二標段)項目
格隆匯10月12日丨金奧博(002917.SZ)公佈,公司於近日收到雲南安化有限責任公司和北京東方華太工程諮詢有限公司出具的《成交通知書》,確定公司為“雲南安化有限責任公司現場混裝重銨油炸藥車、現場混裝乳化炸藥車採購招標(一標段、二標段)”中標供應商,中標金額合計為1264萬元。
上述中標項目標示着公司工藝技術、成套設備、服務水平、質量標準和創新能力持續得到用户認可,體現了公司在同行業中的優勢地位,將進一步提升公司的品牌影響力和核心競爭力,對後續擴大現場混裝炸藥裝備市場份額具有重要意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.